Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Abstract
(R,S)-ketamine (ketamine) and its enantiomer (S)-ketamine (esketamine) can produce rapid and substantial antidepressant effects. However, individual response to ketamine/esketamine is variable, and there are no well-accepted methods to differentiate persons who are more likely to benefit. Numerous potential peripheral biomarkers have been reported, but their current utility is unclear. We conducted a systematic review/meta-analysis examining the association between baseline levels and longitudinal changes in blood-based biomarkers, and response to ketamine/esketamine. Of the 5611 citations identified, 56 manuscripts were included (N = 2801 participants), and 26 were compatible with meta-analytical calculations. Random-effect models were used, and effect sizes were reported as standardized mean differences (SMD). Our assessments revealed that more than 460 individual biomarkers were examined. Frequently studied groups included neurotrophic factors (n = 15), levels of ketamine and ketamine metabolites (n = 13), and inflammatory markers (n = 12). There were no consistent associations between baseline levels of blood-based biomarkers, and response to ketamine. However, in a longitudinal analysis, ketamine responders had statistically significant increases in brain-derived neurotrophic factor (BDNF) when compared to pre-treatment levels (SMD [95% CI] = 0.26 [0.03, 0.48], p = 0.02), whereas non-responders showed no significant changes in BDNF levels (SMD [95% CI] = 0.05 [-0.19, 0.28], p = 0.70). There was no consistent evidence to support any additional longitudinal biomarkers. Findings were inconclusive for esketamine due to the small number of studies (n = 2). Despite a diverse and substantial literature, there is limited evidence that blood-based biomarkers are associated with response to ketamine, and no current evidence of clinical utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dissociative and psychotomimetic effects are common, typically transient, and sometimes accompanied by cardiovascular changes [85,86,87].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Changes in glutamate metabolites, EEG spectral indices, inflammatory markers, BDNF, and network connectivity have been reported, but effect directions, timing, and predictive value vary across cohorts and protocols [85,94,95].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinical response is highly heterogeneous, and robust predictors are lacking, underscoring the need for biomarkers and stratified treatment strategies [85,91,92,93].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [85]
In the citing paper
“Elevation in peripheral BDNF appears to be one of, if not the only, robustly validated blood-based marker for ketamine response.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [90]
In the citing paper
“Importantly, BDNF has displayed adequate central–peripheral correlation, being reflective of CNS glutamatergic activity [90].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“This study followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [58].”
MethodStatistical Power Analysis for the Behavioral Sciences
Cohen, J. (2013) · doi:10.4324/9780203771587 · Cited by 25,373
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Re-epithelialization and immune cell behaviour in an ex vivo human skin model
Rakita, A., Nikolić, N., Mildner, M., Matiasek, J., & Elbe-Bürger, A. (2020) · Scientific Reports · doi:10.1038/s41598-019-56847-4 · Cited by 8,228
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
The Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287 · cited 1×
“Risk of bias assessment Risk of bias was determined by the Quality in Prognostic Studies (QUIPS) tool, which is a standardized assessment of six domains of bias (participants, attrition, prognostic factor measurement, outcome measurement, confounders, and analysis/report) as well as the overall risk of bias [60].”
Method
Research works printed but not linked: 5
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US) www.ncbi.nlm.nih.gov/books/NBK326791/ (2016).
- Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75:e417. · DOI · Paper page
- Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
- Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett. 2013;34:101–7.
- Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398–404. · DOI · Paper page
Cited by
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 97
Medeiros, G. C., Matheson, M., Demo, I., Reid, M. J., Matheson, S., Twose, C., Smith, G. S., Gould, T. D., Zarate, C. A., Barrett, F. S., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00183-9 · Cited by 49
Self-citationPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Importantly, BDNF has displayed adequate central–peripheral correlation, being reflective of CNS glutamatergic activity [90].”
BackgroundSelf-citationPersonalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
Self-citation
Metadata
- Authors
- Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. V., Frye, M. A., Zarate, C. A., & Goes, F. S.
- Affiliations
- University of Maryland, Baltimore (US)
- Yale University (US)
- Johns Hopkins University (US)
- Columbia University Irving Medical Center (US)
- Washington University in St. Louis (US)
- Mayo Clinic (US)
- The University of Texas Health Science Center at Houston (US)
- Pine Rest Christian Mental Health Services (US)
- University of Michigan (US)
- National Institutes of Health (US)
- Corresponding author
- Goes, Fernando S.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2022-06-27
- Volume
- 27
- Issue
- 9
- Pages
- 3658-3669
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC9933928
- OpenAlex
- W4283711009
- Cited by
- 75
- References
- 136
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 21 · 2023: 6 · 2022: 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01BX004062, I01 BX003631)
- National Institutes of Health (5r21mh119441-02)
- National Institute of Mental Health (R21 MH119441, R01MH107615)
- National Institute of Allergy and Infectious Diseases (R21AI145211)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, esketamine, antidepressant response, blood-based biomarkers, brain-derived neurotrophic factor, neurotrophic factors, ketamine metabolites, inflammatory markers, depression, rapid-acting antidepressants, treatment response prediction
- MeSH terms
- Antidepressive Agents, Humans, Ketamine, Biomarkers, Brain-Derived Neurotrophic Factor, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1038/s41380-022-01652-1
- The paper
- Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., Parikh, S. V., Frye, M. A., Zarate, C. A., & Goes, F. S. (2022). Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01652-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.